Sign in to view content

Fluctuations in Central Subfield Thickness Associated With Worse Visual Outcomes in Patients With Diabetic Macular Edema in Clinical Trial Setting

Matthew Starr, MD

Video
Published 2021

Related

Five-Year Outcomes After Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T)
Dante Joseph Pieramici, MD
Annual Meeting Talks
2020
Efficacy, Durability, and Safety of Faricimab in DME: 2-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Jennifer I. Lim, MD, FARVO, FASRS
Updates from the Field
2022
Characteristics and the Need for Supplementation Following 0.19mg Fluocinolone Acetonide (FAc) in Diabetic Macular Edema (DME) Patients
Victor Hugo Gonzalez, MD
Annual Meeting Talks
2021

Category: Diabetic Retinopathy

See more